Rapid Virological Response (RVR) of Daclatasvir and Sofosbuvir Plus Ribavirin in Non-Cirrhotic, Treatment-Naive Patients of Hepatitis C Virus Genotype 3

• Main Authors: Muhammad Sarfraz, Arshad Rabbani, Muhammad Shahzad Manzoor, Zubair Ahmed, Ali Hassan
• Format: Article
• Language: English
• Published: Rawalpindi Medical University 2018-12-01
• Series: Journal of Rawalpindi Medical College
• Subjects: HCV; Genotype 3; RVR; Oral Direct Acting Antivirals; DAA; Daclatasvir
• Online Access: https://www.journalrmc.com/index.php/JRMC/article/view/950

Background :To determine the efficacy of Daclatasvir and Sofosbuvir plus Ribavirin in achieving Rapid Virological Response (RVR) in patients of Hepatitis C genotype 3 who are non-cirrhotic and have not received any previous treatment. Methods: In this descriptive case series study, 100 non cirrhotic, treatment-naïve patients of HCV genotype 3 were enrolled. Each patient was given oral tab Daclatasvir 60 mg once daily,tab Sofosbuvir once daily 400 mg and capsule Ribavirin 400 mg twice daily. HCV RNA PCR quantitative was obtained before treatment and repeated after completion of one month treatment with above mentioned drugs. Results: Mean age of included patients was 42.7 ± 10.68 years (mean ± SD). Females were dominant(59%). The BMI was 26.07 ± 3.00 kg/m2. Out of 100 patients 87% patients achieved Rapid Virological Response (RVR).The data was stratified according to age, gender and BMI. There was no effect of these parameters on the final results. Conclusion: Rapid Virological Response (RVR) of Daclatasvir plus Sofosbuvir and Ribavirin is impressive. However, more studies are required to ascertain the results.